Tests multi-strain probiotics added to standard care for ulcerative colitis
Tests probiotic supplements with usual care in adults with mild to moderate ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Multi-Strain Probiotics Supplementation With Standard Care in Mild to Moderate Ulcerative Colitis
Key facts
- Where
- Cheras, MalaysiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild to moderate ulcerative colitis that is active now. People take a probiotic or a placebo along with their usual treatment.
- Age
- 18 to 90 years
- Sex
- Men and women can join.
- Disease stage
- Ulcerative colitis confirmed by earlier colonoscopy. It involves at least the rectosigmoid and is active on colonoscopy at the start. Disease activity is mild to moderate (PMS score 3 to 8).
- Earlier treatment
- Must have been taking their ulcerative colitis medication for at least 4 weeks before the study. No antibiotics in the last 2 weeks. No probiotics in the last 2 weeks.
Main reasons for not taking part
- Crohn's disease or pouchitis
- Severe disease activity (PMS score above 8)
- Antibiotics within the last 2 weeks
- Medication dose changed in the last 4 weeks or during the 12-week study
- NSAIDs from 1 week before and during the 12-week study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06595719, who can take part
Where in Malaysia
- Hospital Canselor Tuanku Muhriz UKMCheras, MalaysiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University of Malaysia
- Trial code
- NCT06595719
- Record updated
- 12 March 2025
- Original description
Probiotics are one of the adjunctive treatments that have been extensively explored for Ulcerative colitis (UC) disease management. Probiotics, a group of beneficial bacteria, can bring various health benefits when adequately supplied to the body, especially for gut wellness. In particular, for UC patients, gut dysbiosis is one of the contributing factors in their pathogenesis. Thus, the supplementation of probiotics in combination with standard treatment can potentially help in relieving symptoms as well as promoting mucosal healing for long-term remission.Read full original descriptionShow less
Assessing Gut Microbiota, Mucosal Healing Markers, and Metabolites in Mild to Moderate Ulcerative Colitis Treated With Multi-Strain Probiotics
Probiotics are one of the adjunctive treatments that have been extensively explored for Ulcerative colitis (UC) disease management. Probiotics, a group of beneficial bacteria, can bring various health benefits when adequately supplied to the body, especially for gut wellness. In particular, for UC patients, gut dysbiosis is one of the contributing factors in their pathogenesis. Thus, the supplementation of probiotics in combination with standard treatment can potentially help in relieving symptoms as well as promoting mucosal healing for long-term remission.
Inclusion: Diagnosis of UC established by previous colonoscopy, with consistent histology, and clinical course; UC involving at least the rectosigmoid, actively confirmed by colonoscopy at the beginning of the study; Mild to moderate disease activity, defined as a PMS ranging from 3-8; Use of medication at least 4 weeks prior to study.
Exclusion: Use of antibiotics within the last 2 weeks before study entry; Change in dose of medication within the last 4 weeks before study entry and throughout the 12-week study period; Use of probiotics preparation either prescribed or over the counter within 2 weeks before the study entry; Use of NSAIDs for 1 week before and throughout the 12-week study period; Crohn's disease or pouchitis; Severe disease activity as defined in PMS, more than 8.